(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 December 2015 (30.12.2015)

WIPO | PCT

(10) International Publication Number
WO 2015/198146 A2

(51) International Patent Classification:
A61K 39/395 (2006.01)

(21) International Application Number:
PCT/IB2015/001377

(22) International Filing Date:
26 June 2015 (26.06.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/018,253	27 June 2014 (27.06.2014)	US
14306477.2	24 September 2014 (24.09.2014)	EP
62/102,097	11 January 2015 (11.01.2015)	US
62/102,555	12 January 2015 (12.01.2015)	US

(71) Applicant: **SANOFI** [FR/FR]; 54 Rue La Boetie, F-75008 Paris (FR).

(72) Inventors: **ESPERET, Corrine**; C/o Sanofi, 54 Rue La Boetie, F-75008 Paris (FR). **JAGERSCHMIET, Alexandre**; C/o Sanofi, 54 Rue La Boetie, F-75008 Paris (FR). **SOUBRANE, Christina**; C/o Sanofi, 54 Rue La Boetie, F-75008 Paris (FR). **SUBRAMANIAM, Arun**; C/o Sanofi, 55 Corporate Drive, Mail Code: 55a-505a, Bridgewater, NJ 08807 (US).

(74) Agent: **MASZYNA, Frank**; c/o Sanofi-Aventis Deutschland GmbH, Industriepark Höchst, Building 703, 65926 Frankfurt am Main (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-IL4-IL 13 BISPECIFIC ANTIBODIES

(57) Abstract: Disclosed herein are safe doses of dual-V-region antibody-like binding proteins or fragments thereof, as well as methods for assessing binding of dual-V- region antibody-like proteins or fragments thereof to their targets, and methods of treating idiopathic pulmonary fibrosis (IPF) by administering safe doses of dual-V- region antibody-like binding proteins or fragments thereof. In some embodiments, the dual-V-region antibody-like binding proteins or fragments thereof bind both IL-4 and IL-13.

WO 2015/198146 A2